Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
-Teplizumab Biologics License Application (BLA) resubmission accepted for review by FDA and user fee goal date set for August 17, 2022– -Company to host teplizumab commercial launch investor event on Thursday, May…